Paliperidone ER in the treatment of borderline personality disorder: A pilot study of efficacy and tolerability

Depression Research and Treatment

Volumn 2011, Issue , 2011, Pages

  Bellino, Silvio ^a   Bozzatello, Paola ^a   Rinaldi, Camilla ^a   Bogetto, Filippo ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84869133559     PISSN: 20901321     EISSN: 2090133X     Source Type: Journal    
DOI: 10.1155/2011/680194     Document Type: Article

References (69)

1. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders 2000 4th Washington, DC, USA American Psychiatric Association. Text Revision (DSM-IV-TR)
2. American Psychiatric Association, Practice Guidelines for the Treatment of Patients with Borderline Personality Disorder 2001 Arlington, Va, USA American Psychiatric Association
3. Oldham J. M., Guideline Watch: Practice Guideline for the Treatment of Patients with Borderline Personality Disorder 2005 Arlington, Va, USA American Psychiatric Association
4. Meltzer H. Y., McGurk S. R., The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophrenia Bulletin 1999 25 2 233 255 2-s2.0-0032977410 (Pubitemid 29272503)
5. Correll C. U., Leucht S., Kane J. M., Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. American Journal of Psychiatry 2004 161 3 414 425 2-s2.0-1542373740 10.1176/appi.ajp.161.3.414 (Pubitemid 38326094)
6. Van Den Eynde F., frederique.vandeneynde@iop.kcl.ac.uk De Saedeleer S., Naudts K., Day J., Vogels C., Van Heeringen C., Audenaert K., Quetiapine treatment and improved cognitive functioning in borderline personality disorder. Human Psychopharmacology 2009 24 8 646 649 10.1002/hup.1075
7. Szigethy E. M., Schulz S. C., Risperidone in comorbid borderline personality disorder and dysthymia. Journal of Clinical Psychopharmacology 1997 17 4 326 327 2-s2.0-0030814284 10.1097/00004714-199708000-00019 (Pubitemid 27312437)
8. Rocca P., Marchiaro L., Cocuzza E., Bogetto F., Treatment of borderline personality disorder with risperidone. Journal of Clinical Psychiatry 2002 63 3 241 244 2-s2.0-0036112314 (Pubitemid 34407084)
9. Friedel R. O., Jackson W. T., Huston C. S., May R. S., Kirby N. L., Stoves A., Risperidone treatment of borderline personality disorder assessed by a borderline personality disorder-specific outcome measure: a pilot study. Journal of Clinical Psychopharmacology 2008 28 3 345 347 2-s2.0-51449121218 10.1097/JCP.0b013e318173083e
10. Jutila A., Söderlund T., Pakkanen A. L., Huttunen M., Kinnunen P. K. J., Comparison of the effects of clozapine, chlorpromazine, and haloperidol on membrane lateral heterogeneity. Chemistry and Physics of Lipids 2001 112 2 151 163 2-s2.0-0034873514 10.1016/S0009-3084(01)00175-X (Pubitemid 32817150)
11. Megens A. A. H. P., Awouters F. H. L., Schotte A., Meert T. F., Dugovic C., Niemegeers C. J. E., Leysen J. E., Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology 1994 114 1 9 23 2-s2.0-0028332094 (Pubitemid 24150515)
12. Schotte A., Janssen P. F. M., Gommeren W., Luyten W. H. M. L., Van Gompel P., Lesage A. S., De Loore K., Leysen J. E., Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 1996 124 1-2 57 73 2-s2.0-0029930927 10.1007/BF02245606 (Pubitemid 26112775)
13. Leysen J. E., Ellenbroek B. A., Cools A. R., Receptor profile of antipsychotics. Atypical Antipsychotics 2000 Basel, Switzerland Birkäuser 57 81
14. Vermeir M., Boom S., Naessens I., Talluri K., Eerdekens M., Absorbtion, metabolism and excretion of a single oral dose of 14C-paliperidone 1mg in healthy subjects. European Neuropsychopharmacology 2005 30 191 192
15. Marder S. R., Kramer M., Ford L., Eerdekens E., Lim P., Eerdekens M., Lowy A., Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biological Psychiatry 2007 62 12 1363 1370 2-s2.0-36048941530 10.1016/j.biopsych.2007.01.017 (Pubitemid 350180724)
16. Lautenschlager M., Heinz A., Paliperidone-ER: first atypical antipsychotic with oral extended release formulation. Expert Review of Neurotherapeutics 2008 8 2 193 200 2-s2.0-39549095838 10.1586/14737175.8.2.193 (Pubitemid 351281108)
17. Nasrallah H. A., Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Molecular Psychiatry 2008 13 1 27 35 2-s2.0-37249034101 10.1038/sj.mp.4002066 (Pubitemid 350275185)
18. Knegtering R., Baselmans P., Castelein S., Bosker F., Bruggeman R., Van Den Bosch R. J., Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. American Journal of Psychiatry 2005 162 5 1010 1012 2-s2.0-18744408824 10.1176/appi.ajp.162.5.1010 (Pubitemid 40676220)
19. Melkersson K. I., Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite. Human Psychopharmacology 2006 21 8 529 532 2-s2.0-33846093024 10.1002/hup.811 (Pubitemid 46062141)
20. Kane J., Canas F., Kramer M., Ford L., Gassmann-Mayer C., Lim P., Eerdekens M., Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophrenia Research 2007 90 1-3 147 161 2-s2.0-33846590147 10.1016/j.schres.2006.09.012 (Pubitemid 46178537)
21. Davidson M., Emsley R., Kramer M., Ford L., Pan G., Lim P., Eerdekens M., Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophrenia Research 2007 93 1-h;3 117 130 2-s2.0-34249275309 10.1016/j.schres.2007.03.003 (Pubitemid 46817944)
22. Dolder C., Nelson M., Deyo Z., Paliperidone for schizophrenia. American Journal of Health-System Pharmacy 2008 65 5 403 413 2-s2.0-40349102037 10.2146/ajhp070261 (Pubitemid 351358341)
23. Berwaerts J., Cleton A., Rossenu S., Talluri K., Remmerie B., Janssens L., Boom S., Kramer M., Eerdekens M., A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia. Journal of Psychopharmacology 2010 24 7 1011 1018 2-s2.0-77953747495 10.1177/ 0269881109106914
24. Karlsson P., Dencker E., Nyberg S., Pharmacokinetic and dopamine D2 and serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects. European Neuropsychopharmacology 2005 15 385
25. Karlsson P., Dencker E., Nyberg S., Pharmacokinetics, dopamine D2 and serotonin 5-HT2A receptor occupancy and safety profile of paliperidone extended-release in healthy subjects. Schizophrenia Research 2006 81 1 85 86
26. Conley R., Gupta S. K., Sathyan G., Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. Current Medical Research and Opinion 2006 22 10 1879 1892 2-s2.0-33750517755 10.1185/030079906X132613 (Pubitemid 44663390)
27. Canuso C. M., Bossie C. A., Turkoz I., Alphs L., Paliperidone extended-release for schizophrenia: effects on symptoms and functioning in acutely ill patients with negative symptoms. Schizophrenia Research 2009 113 1 56 64 2-s2.0-67649850363 10.1016/j.schres.2009.05.021
28. Pani L., Marchese G., Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release. Expert Opinion on Drug Delivery 2009 6 3 319 331 2-s2.0-66149109246 10.1517/17425240902780158
29. Meltzer H. Y., Bobo W. V., Nuamah I. F., Lane R., Hough D., Kramer M., Eerdekens M., Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. Journal of Clinical Psychiatry 2008 69 5 817 829 2-s2.0-45249095185 (Pubitemid 351838691)
30. First M. B., Gibbon M., Spitzer R. L., Williams J. B. W., Benjamin L. S., Structured Clinical Interview for DSM-IV disorders Axis II (SCID-II) 1997 Arlington, Va, USA American Psychiatric Press
31. Guy W., US Dept Health, Education, and Welfare publication (ADM), Clinical global impression (C.G.I.). ECDEU Assessment Manual for Psychopharmacology 1976 Rockville, Md, USA National Institute of Mental Health 218 222
32. Ventura J., Green M., Shaner A., Liberman R., Training and quality assurance with the Brief Psychiatry Rating Scale: the drift busters International Journal of Psychiatric Research 1993 3 221
33. Hamilton M., A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry 1960 23 56 62 2-s2.0-72949151592
34. Hamilton M., The assessment of anxiety states by rating. The British Journal of Medical Psychology 1959 32 1 50 55 2-s2.0-51549099524
35. Goldman H. H., Skodol A. E., Lave T. R., Revising axis V for DSM-IV: a review of measures of social functioning. American Journal of Psychiatry 1992 149 9 1148 1156 2-s2.0-0026786902
36. Barratt E. S., Factor analysis of some psychometric measures of impulsiveness and anxiety. Psychological Reports 1965 16 547 554 2-s2.0-76549195945
37. Arntz A., Van den Hoorn M., Cornelis J., Verheul R., Van den Bosch W. M. C., De Bie A. J. H. T., Reliability and validity of the borderline personality disorder severity index. Journal of Personality Disorders 2003 17 1 45 59 2-s2.0-0037300687 10.1521/pedi.17.1.45.24053 (Pubitemid 36343239)
38. Barratt E. S., Monahan J., Steadman H. J., Impulsiveness and aggression. Violence and Mental Disorder: Developments in Risk Assessment 1994 Chicago, Ill, USA University of Chicago Press 61 79
39. Patton J. H., Stanford M. S., Barratt E. S., Factor structure of the Barratt Impulsiveness Scale. Journal of Clinical Psychology 1994 51 6 768 774 2-s2.0-0029567978
40. Fossati A., Di Ceglie A., Acquarini E., Barratt E. S., Psychometric properties of an Italian version of the Barrat Impulsiveness Scale-11 (BIS-11) in nonclinical subjects. Journal of Clinical Psychology 2001 57 6 815 828 2-s2.0-0035010252 10.1002/jclp.1051 (Pubitemid 32466562)
41. Guy W., US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, Dosage Record and Treatment Emergent Symptoms scale (DOTES). ECDEU Assessment Manual for Psychopharmacology-Revised 1976 Rockville, Md, USA National Institute of Mental Health 223 244
42. Haddad P. M., Wieck A., Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004 64 20 2291 2314 2-s2.0-6344253360 10.2165/00003495-200464200-00003 (Pubitemid 39388605)
43. Mancini T., Casanueva F. F., Giustina A., Hyperprolactinemia and prolactinomas. Endocrinology and Metabolism Clinics of North America 2008 37 1 67 99 2-s2.0-38549116137 10.1016/j.ecl.2007.10.013 (Pubitemid 351146629)
44. Harrington C. A., ch562@nova.edu English C., Tolerability of paliperidone: a meta-analysis of randomized, controlled trials. International Clinical Psychopharmacology 2010 25 6 334 341 10.1097/YIC.0b013e32833db3d8
45. Díaz-Marsá M., Galian M., Montes A., Fernández R., Arza R., López-Ibor J. J., Carrasco J. L., Long-acting injectable risperidone in treatment resistant borderline personality disorder. A small series report. Actas Espanolas de Psiquiatria 2008 36 2 70 74 2-s2.0-42549135091
46. Frankerburg F. R., Zanarini M. C., Clozapine treatment of borderline patients: a preliminary study. Comprehensive Psychiatry 1993 34 6 402 405 2-s2.0-0027425005 10.1016/0010-440X(93)90065-C (Pubitemid 23358021)
47. Parker G. F., Clozapine and borderline personality disorder. Psychiatric Services 2002 53 3 348 349 2-s2.0-0036190318 10.1176/appi.ps.53.3.348 (Pubitemid 34184696)
48. Schulz S. C., Camlin K. L., Berry S. A., Jesberger J. A., Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biological Psychiatry 1999 46 10 1429 1435 2-s2.0-0032745961 10.1016/S0006-3223(99)00128-6
49. Bogenschutz M. P., Nurnberg H. G., Olanzapine versus placebo in the treatment of borderline personality disorder. Journal of Clinical Psychiatry 2004 65 1 104 109 2-s2.0-1442333532 10.4088/JCP.v65n0118
50. Adityanjee A., Schulz S. C., Clinical use of quetiapine in disease states other than schizophrenia. Journal of Clinical Psychiatry 2002 63 13 32 38 2-s2.0-0036460307 (Pubitemid 35471368)
51. Hilger E., Barnas C., Kasper S., Quetiapine in the treatment of borderline personality disorder. The World Journal of Biological Psychiatry 2003 4 1 42 44 2-s2.0-0038170049
52. Villeneuve E., Lemelin S., Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as main target. Journal of Clinical Psychiatry 2005 66 10 1298 1303 2-s2.0-27544468326 (Pubitemid 41546510)
53. Bellino S., Paradiso E., Bogetto F., Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: a pilot study. Journal of Clinical Psychiatry 2006 67 7 1042 1046 2-s2.0-33747187764 (Pubitemid 44230874)
54. Perrella C., Carrus D., Costa E., Schifano F., Quetiapine for the treatment of borderline personality disorder; an open-label study. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2007 31 1 158 163 2-s2.0-33845666831 10.1016/j.pnpbp.2006.08.012 (Pubitemid 44959269)
55. Adityanjee A., Romine A., Brown E., Thuras P., Lee S., Schulz S. C., Quetiapine in patients with borderline personality disorder: an open-label trial. Annals of Clinical Psychiatry 2008 20 4 219 226 2-s2.0-57149139518 10.1080/10401230802467545
56. Van Den Eynde F., Senturk V., Naudts K., Vogels C., Bernagie K., Thas O., Van Heeringen C., Audenaert K., Efficacy of quetiapine for impulsivity and affective symptoms in borderline personality disorder. Journal of Clinical Psychopharmacology 2008 28 2 147 155 2-s2.0-40949127907 10.1097/JCP. 0b013e318166c4bf (Pubitemid 351417119)
57. Mobascher A., Mobascher J., Schlemper V., Winterer G., Malevani J., Aripiprazole pharmacotherapy of borderline personality disorder: a series of three consecutive case reports. Pharmacopsychiatry 2006 39 3 111 112 2-s2.0-33745132142 10.1055/s-2006-941485 (Pubitemid 43901623)
58. Nickel M. K., Muehlbacher M., Nickel C., Kettler C., Gil F. P., Bachler E., Buschmann W., Rother N., Fartacek R., Egger C., Anvar J., Rother W. K., Loew T. H., Kaplan P., Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. American Journal of Psychiatry 2006 163 5 833 838 2-s2.0-33744985826 10.1176/appi.ajp.163.5.833 (Pubitemid 44464531)
59. Nickel M. K., Aripiprazole treatment of patients with borderline personality disorder. Journal of Clinical Psychiatry 2007 68 11 1815 1816 2-s2.0-37048998728 (Pubitemid 350247518)
60. Bellino S., Paradiso E., Bogetto F., Efficacy and tolerability of aripiprazole augmentation in sertraline-resistant patients with borderline personality disorder. Psychiatry Research 2008 161 2 206 212 2-s2.0-55449131048 10.1016/j.psychres.2007.07.006
61. Zanarini M. C., Frankenburg F. R., Parachini E. A., A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. Journal of Clinical Psychiatry 2004 65 7 903 907 2-s2.0-4444360539 10.4088/JCP.v65n0704
62. Soler J., Pascual J. C., Campins J., Barrachina J., Puigdemont D., Alvarez E., Pérez V., Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. American Journal of Psychiatry 2005 162 6 1221 1224 2-s2.0-20044384036 10.1176/appi.ajp.162.6.1221 (Pubitemid 40770712)
63. Benedetti F., Sforzini L., Colombo C., Maffei C., Smeraldi E., Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. Journal of Clinical Psychiatry 1998 59 3 103 107 2-s2.0-0031900038 (Pubitemid 28150854)
64. Zanarini M. C., Frankenburg F. R., Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. Journal of Clinical Psychiatry 2001 62 11 849 854 2-s2.0-0035196941 (Pubitemid 33131170)
65. Pascual J. C., Oller S., Soler J., Barrachina J., Alvarez E., Pérez V., Ziprasidone in the acute treatment of borderline personality disorder in psychiatric emergency services. Journal of Clinical Psychiatry 2004 65 9 1281 1282 2-s2.0-5444234232
66. Bostwick J. R., Guthrie S. K., Ellingrod V. L., Antipsychotic-induced hyperprolactinemia. Pharmacotherapy 2009 29 1 64 73 2-s2.0-59949094252 10.1592/phco.29.1.64
67. Spina E., Cavallaro R., The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia. Expert Opinion on Drug Safety 2007 6 6 651 662 2-s2.0-38449090708 10.1517/14740338.6.6.651 (Pubitemid 351308277)
68. Marino J., Caballero J., Paliperidone extended-release for the treatment of schizophrenia. Pharmacotherapy 2008 28 10 1283 1298 2-s2.0-54749087953 10.1592/phco.28.10.1283
69. Tzimos A., Samokhvalov V., Kramer M., Ford L., Gassmann-Mayer C., Lim P., Eerdekens M., Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension. American Journal of Geriatric Psychiatry 2008 16 1 31 43 2-s2.0-39749099978 10.1097/JGP. 0b013e31815a3e7a.